Telehealth for ADHD: A Game-Changer or a Diagnostic Dilemma?
The rise of telehealth has been nothing short of revolutionary, especially in the realm of mental health care. But when it comes to ADHD diagnosis and treatment, the waters get murky. Is telehealth a reliable ally or a potential pitfall? This question took center stage at the American Professional Society of ADHD and Related Disorders (APSARD) 2026 Annual Conference, where experts gathered to dissect the role of technology in ADHD care. Among them was Barry K. Herman, MD, MMM, Chief Medical Officer of Mentavi Health, who presented groundbreaking findings on an online ADHD assessment tool. But here's where it gets controversial: while telehealth offers unprecedented access and convenience, concerns about diagnostic rigor and the prescribing of stimulants have sparked heated debates.
The Telehealth Boom: A Double-Edged Sword
Telehealth isn’t new, but its adoption skyrocketed during the COVID-19 pandemic. Both patients and practitioners embraced it for its accessibility and convenience—two critical factors in today’s strained mental health care system. However, this rapid expansion exposed inconsistencies in telehealth practices, particularly in ADHD care. Some providers, driven more by profit than patient welfare, tarnished the reputation of telehealth with questionable diagnostic and treatment methods. This raised a critical question: How accurate and reliable are telehealth-based ADHD diagnoses compared to traditional clinical interviews?
Bridging the Evidence Gap
Dr. Herman’s study aimed to address this very gap. Despite nearly half of adults with ADHD using telehealth, as reported by the CDC, there was a startling lack of research comparing telehealth diagnostics to standard clinical practices. Mentavi Health’s study, published in the Journal of Clinical Psychiatry, was a pioneering effort in this direction. The findings? Their online asynchronous assessment tool demonstrated 80% sensitivity and a 95% positive predictive value, with a strikingly low false positive rate of just 12%—far surpassing the 56% rate observed in traditional clinical interviews. And this is the part most people miss: the study highlighted the alarming variability in ADHD diagnosis, often conducted by professionals lacking sufficient expertise.
The Human Touch in a Digital World
One of the most contentious issues in telehealth is the role of artificial intelligence. Critics fear AI might replace human judgment, but Dr. Herman reassures that Mentavi Health’s model is firmly rooted in human oversight. Their AI ethics committee ensures that every diagnosis involves a trained clinician, not a chatbot. This blend of technology and human expertise is key to maintaining trust and accuracy in ADHD care.
The Comorbidity Challenge
ADHD rarely travels alone; 80% of patients have at least one co-occurring psychiatric condition. Dr. Herman’s tool addresses this complexity by identifying common comorbidities, providing clinicians with valuable data to refine their treatment plans. But here’s the kicker: Can technology truly untangle the intricate web of ADHD and its comorbidities? The jury is still out, and this is where the conversation gets heated.
The Road Ahead: Questions and Challenges
As telehealth continues to evolve, so do the questions it raises. How can we standardize diagnostic practices across platforms? What role should AI play in mental health care? And most importantly, how do we ensure that technology enhances, rather than replaces, the human connection in medicine? Dr. Herman’s work is a step in the right direction, but it’s just the beginning. What’s your take? Do you believe telehealth can revolutionize ADHD care, or does it pose more risks than rewards? Share your thoughts in the comments—let’s keep the conversation going.
